Key Highlights

● Novavax soared to about $12.87 in afternoon trading as Vaccine stocks rallied across the board.

● No announcement, filing, analyst action, trial result or scheduled event from Novavax explained the move, according to one report.

● Moderna jumped $28.00 to close at $225.00, its highest level since 2021, on its Nasdaq-100 debut.

● The Russell 2000 rose 12.85 points to 2,806.98 but posted its fifth straight weekly decline.

Novavax (NASDAQ:NVAX) was one of Friday's most eye-catching movers, soaring to about $12.87 in afternoon trading as vaccine stocks rallied across the board. The surge came on a day when investors scrambled to position for what could become a major government-backed push into cancer vaccines.

The spark was a media report that the National Institutes of Health plans a public-private initiative, beginning in December, to fast-track research into cancer vaccines and treatments. According to the report, the effort would initially focus on pancreatic, liver and colorectal cancers as well as some childhood tumors, and aims to replicate the success of the Covid-19 vaccine effort.

Did anything company-specific drive it?

One market report tied Novavax's gain to the NIH report. But not every account saw a direct link. Another noted that no announcement, filing, analyst action, trial result or scheduled event from the company explained the move in the shares. That leaves the rally best understood as a sector-wide bet rather than a reaction to new Novavax data.

Novavax is best known for its protein-based Covid-19 vaccine, which uses a different technology from the messenger RNA, or mRNA, shots developed by Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) with BioNTech (NASDAQ:BNTX). Its shares have been volatile for years as Covid vaccine Demand has fallen, which helps explain why the stock can swing so sharply when sentiment toward the whole vaccine group turns.

Moderna led the charge

The biggest name in the rally was Moderna, which jumped $28.00 to close at $225.00, its highest level since 2021. Moderna also officially joined the Nasdaq-100 on Friday morning, replacing Warner Bros. Discovery (NASDAQ:WBD). BioNTech, Arcturus Therapeutics (NASDAQ:ARCT) and Vaxcyte (NASDAQ:PCVX) climbed too, and the rally spilled over into larger drugmakers including Pfizer, Merck (NYSE:MRK) and Gilead Sciences (NASDAQ:GILD).

Health care was one of the strongest sectors in the S&P 500 on Friday, helped as well by Humana (NYSE:HUM)'s surge after new Medicare star ratings. For the week, health care ranked among the leading sectors.

The NIH initiative, as reported, is still a plan. Details about which companies might take part, how funding would work and how quickly any vaccines could reach patients have not been made public.

Broader market

Stocks rose broadly. The Nasdaq Composite gained 172.83 points to 27,366.17, the S&P 500 added 46.18 points to 7,811.54, just shy of Tuesday's record close, and the Dow climbed 423.31 points to 51,654.95. The small-cap Russell 2000 rose 12.85 points to 2,806.98 but still posted its fifth straight weekly decline. On the Nasdaq, 2,756 stocks rose and 1,997 fell.

The macro backdrop stayed demanding. The 10-year Treasury Yield held near a 24-year high, the Fed raised rates in September for the first time since 2023, and consumer sentiment fell to a five-month low of 46.3 in the University of Michigan's preliminary October survey. Higher rates tend to weigh on small, cash-hungry biotech firms, making Friday's rush into the group all the more notable.

Official NIH Confirmation Is the Key Open Item for Novavax and the Vaccine Group

Monday, October 12 is Columbus Day, with stocks open and the Bond Market closed. September consumer prices arrive Wednesday, October 14, followed by producer prices and retail sales on Thursday. Bank Earnings run from October 13 to 16, and the Fed meets on October 27 and 28. Investors will look for official confirmation and details of the NIH-linked cancer-vaccine initiative, including any companies named as partners, ahead of its expected December start.